Home › Retrophin Signs U.S. License Agreement For Syntocinon Nasal Spray (Oxytocin)
 

Keywords :   


Retrophin Signs U.S. License Agreement For Syntocinon Nasal Spray (Oxytocin)

2013-12-19 08:09:31| drugdiscoveryonline News Articles

Retrophin, Inc. recently announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon™ Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties. Syntocinon™ Nasal Spray was approved in the U.S. in 1960 to assist initial postpartum milk ejection, but was discontinued by Novartis in 1997 for

Tags: agreement license signs spray

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Tropical Depression Twelve Public Advisory Number 1
29.09Summary for Tropical Depression Twelve (AT2/AL122024)
29.09Tropical Depression Twelve Wind Speed Probabilities Number 1
29.09Tropical Storm Joyce Forecast Discussion Number 10
29.09Tropical Depression Twelve Forecast Discussion Number 1
29.09Tropical Depression Twelve Graphics
29.09Tropical Storm Joyce Graphics
29.09Tropical Storm Joyce Wind Speed Probabilities Number 10
More »